Summary
Constitutive activation of the mitogen-activated protein (MAP) kinase signaling pathway by oncogenic stimulation is widespread in human cancers. With the recently demonstrated links between MAP kinase, histone phosphorylation, gene transcription factors, and hTERT gene promoter activity, abnormal MAP kinase activity is likely to be one of the essential forces that impact on hTERT gene transcription in transformed human cells. Several proteins have been implicated as playing important roles in MAP kinase signaling to hTERT gene, including Ets and activator protein-1 (AP-1). Inhibition of these signaling mechanisms may have a consequential effect on hTERT gene expression and telomerase activity. In this study, we brief the current progress and strategy in molecular targeting to the interface between MAP kinase and hTERT gene promoter in cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Goueli, B. S., and Janknecht, R. (2004) Upregulation of the catalytic telomerase subunit by the transcription factor ER81 and oncogenic HER2/Neu, Ras, or Raf. Mol Cell Biol 24, 25–35.
Maida, Y., Kyo, S., Kanaya, T., Wang, Z., Yatabe, N., Tanaka, M., Nakamura, M., Ohmichi, M., Gotoh, N., Murakami, S., and Inoue, M. (2002) Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway. Oncogene 21, 4071–9.
Bayne, S., and Liu, J. P. (2005) Hormones and growth factors regulate telomerase activity in ageing and cancer. Mol Cell Endocrinol 240, 11–22.
Li, H., Xu, D., Toh, B. H., and Liu, J. P. (2006) TGF-â and cancer: is Smad3 a repressor of hTERT gene? Cell Res 16, 169–73.
Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., and Velculescu, V. E. (2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418, 934.
Liu, J. P. (1999) Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J 13, 2091–104.
Li, H., Pinto, A. R., Duan, W., Li, J., Toh, B. H., and Liu, J. P. (2005) Telomerase down-regulation does not mediate PC12 pheochromocytoma cell differentiation induced by NGF, but requires MAP kinase signalling. J Neurochem 95, 891–901.
Alfonso-De Matte, M. Y., Yang, H., Evans, M. S., Cheng, J. Q., and Kruk, P. A. (2002) Telomerase is regulated by c-Jun NH2-terminal kinase in ovarian surface epithelial cells. Cancer Res 62, 4575–8.
Ge, Z., Liu, C., Bjorkholm, M., Gruber, A., and Xu, D. (2006) Mitogen-activated protein kinase cascade-mediated histone h3 phosphorylation is critical for telomerase reverse transcriptase expression/telomerase activation induced by proliferation. Mol Cell Biol 26, 230–7.
Takakura, M., Kyo, S., Inoue, M., Wright, W. E., and Shay, J. W. (2005) Function of AP-1 in transcription of the telomerase reverse transcriptase gene (TERT) in human and mouse cells. Mol Cell Biol 25, 8037–43.
Fu, W., Lu, C., and Mattson, M. P. (2002) Telomerase mediates the cell survival-promoting actions of brain-derived neurotrophic factor and secreted amyloid precursor protein in develo** hippocampal neurons. J Neurosci 22, 10710–9.
Woo, C. W., Lucarelli, E., and Thiele, C. J. (2004) NGF activation of TrkA decreases N-myc expression via MAPK path leading to a decrease in neuroblastoma cell number. Oncogene 23, 1522–30.
Wang, J., Feng, H., Huang, X. Q., **ang, H., Mao, Y. W., Liu, J. P., Yan, Q., Liu, W. B., Liu, Y., Deng, M., Gong, L., Sun, S., Luo, C., Liu, S. J., Zhang, X. J., and Li, D. W. (2005) Human telomerase reverse transcriptase immortalizes bovine lens epithelial cells and suppresses differentiation through regulation of the ERK signaling pathway. J Biol Chem 280, 22776–87.
Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., and Saltiel, A. R. (1995) PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 270, 27489–94.
Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., and Saltiel, A. R. (1995) A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 92, 7686–9.
Johnson, G. L., and Lapadat, R. (2002) itogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298, 1911–2.
Torres, C., Li, M., Walter, R., and Sierra, F. (2000) Modulation of the ERK pathway of signal transduction by cysteine proteinase inhibitors. J Cell Biochem 80, 11–23.
Wityak, J., Hobbs, F. W., Gardner, D. S., Santella, J. B., 3rd, Petraitis, J. J., Sun, J. H., Favata, M. F., Daulerio, A. J., Horiuchi, K. Y., Copeland, R. A., Scherle, P. A., Jaffe, B. D., Trzaskos, J. M., Magolda, R. L., Trainor, G. L., and Duncia, J. V. (2004) Beyond U0126. Dianion chemistry leading to the rapid synthesis of a series of potent MEK inhibitors. Bioorg Med Chem Lett 14, 1483–6.
Duncia, J. V., Santella, J. B., 3rd, Higley, C. A., Pitts, W. J., Wityak, J., Frietze, W. E., Rankin, F. W., Sun, J. H., Earl, R. A., Tabaka, A. C., Teleha, C. A., Blom, K. F., Favata, M. F., Manos, E. J., Daulerio, A. J., Stradley, D. A., Horiuchi, K., Copeland, R. A., Scherle, P. A., Trzaskos, J. M., Magolda, R. L., Trainor, G. L., Wexler, R. R., Hobbs, F. W., and Olson, R. E. (1998) MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products. Bioorg Med Chem Lett 8, 2839–44.
Ge, X., Fu, Y. M., and Meadows, G. G. (2002) U0126, a mitogen-activated protein kinase kinase inhibitor, inhibits the invasion of human A375 melanoma cells. Cancer Lett 179, 133–40.
Shin, M., Yan, C., and Boyd, D. (2002) An inhibitor of c-jun aminoterminal kinase (SP600125) represses c-Jun activation, DNA-binding and PMA-inducible 92-kDa type IV collagenase expression. Biochim Biophys Acta 1589, 311–6.
Vincenti, M. P., and Brinckerhoff, C. E. (2001) The potential of signal transduction inhibitors for the treatment of arthritis: is it all just JNK? J Clin Invest 108, 181–3.
Cirillo, P. F., Pargellis, C., and Regan, J. (2002) The non-diaryl heterocycle classes of p38 MAP kinase inhibitors. Curr Top Med Chem 2, 1021–35.
Ward, K. W., Proksch, J. W., Azzarano, L. M., Salyers, K. L., McSurdy-Freed, J. E., Molnar, T. M., Levy, M. A., and Smith, B. R. (2001) SB-239063, a potent and selective inhibitor of p38 map kinase: preclinical pharmacokinetics and species-specific reversible isomerization. Pharm Res 18, 1336–44.
Adams, J. L., Badger, A. M., Kumar, S., and Lee, J. C. (2001) p38 MAP kinase: molecular target for the inhibition of pro-inflammatoy cytokines. Prog Med Chem 38, 1–60.
Acknowledgments
This work was supported by grants from the Australia Research Council and National Health & Medical Research Council of Australia.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer
About this protocol
Cite this protocol
Xu, D., Li, H., Liu, JP. (2007). Inhibition of Telomerase by Targeting MAP Kinase Signaling. In: Andrews, L.G., Tollefsbol, T.O. (eds) Telomerase Inhibition. Methods in Molecular Biology™, vol 405. Humana Press. https://doi.org/10.1007/978-1-60327-070-0_12
Download citation
DOI: https://doi.org/10.1007/978-1-60327-070-0_12
Publisher Name: Humana Press
Print ISBN: 978-1-58829-683-2
Online ISBN: 978-1-60327-070-0
eBook Packages: Springer Protocols